DÄ internationalArchiveReferences

Original article

Opioid Rotation in Cancer Pain Treatment

Dtsch Arztebl Int 2018; 115: 135-42. DOI: 10.3238/arztebl.2018.0135

Schuster, M; Bayer, O; Heid, F; Laufenberg-Feldmann, R

1.Bruera ED, Portenoy RK: Cancer pain. Assessment and management. 2nd edition; New York: Cambridge University Press 2010.
2.Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S: Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93: 247–57 CrossRef
3.Fine PG, Portenoy RK: Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38: 418–25 CrossRef MEDLINE PubMed Central
4.Nalamachu SR: Opioid rotation in clinical practice. Adv Ther 2012; 29: 849–63 CrossRef MEDLINE
5.Knotkova H, Fine PG, Portenoy RK: Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38: 426–39 CrossRef MEDLINE
6.Bohnert AS, Valenstein M, Bair MJ, et al.: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315–21 CrossRef MEDLINE
7.Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpf A, Petzke F: Long-term opioid use in non-cancer pain. Dtsch Arztebl Int 2014; 111: 732–40 VOLLTEXT
8.Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; 3: CD004847 CrossRef
9.Mercadante S, Caraceni A: Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011; 25: 504–15 CrossRef MEDLINE
10.Dale O, Moksnes K, Kaasa S: European palliative care research collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 2011; 25: 494–503 CrossRef MEDLINE
11.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097 CrossRef MEDLINE PubMed Central
12.Shea BJ, Grimshaw JM, Wells GA, et al.: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10 CrossRef MEDLINE PubMed Central
13.Shea BJ, Hamel C, Wells GA, et al.: AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62: 1013–20 CrossRef MEDLINE
14.Higgins JPT, Altman DG, Gøtzsche PC, et al.: The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343 CrossRef
15.Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J: Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73: 712–6 CrossRef
16. Phillips B, Ball C, Sackett D, et al.: Oxford centre for evidence-based medicine—levels of evidence, 2009. www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (last accessed on 31 July 2017).
17.McLean S, Twomey F: Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage 2015; 50: 248–59.e1 CrossRef MEDLINE
18.Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T: Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig 2014; 34: 501–11 CrossRef MEDLINE PubMed Central
19.Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S: How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial. Eur J Cancer 2011; 47: 2463–70 CrossRef MEDLINE
20. Poulain P, Berleur MP, Lefki S, et al.: Efficacy and safety of two methadone titration methods for the treatment of cancer-related pain: the EQUIMETH2 trial (methadone for cancer-related pain). J Pain Symptom Manage 2016; 52: 626–36.e1 CrossRef MEDLINE
21.Slatkin NE, Rhiner MI, Gould EM, Ma T, Ahdieh H: Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. J Opioid Manag 2010; 6: 181–91 CrossRef
22.Lee KH, Kim MK, Hyun MS, et al.: Clinical effectiveness and safety of OROS(R) hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients. J Opioid Manag 2012; 8: 243–52 CrossRef MEDLINE
23.Lundorff L, Sjogren P, Hansen OB, Jonsson T, Nielsen PR, Christrup L: Switching from high doses of pure mu-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag 2013; 9: 255–62 CrossRef MEDLINE
24.Mercadante S, Porzio G, Adile C, et al.: Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin 2014; 30: 2063–8 CrossRef MEDLINE
25.Minami S, Kijima T, Nakatani T, et al.: Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain. BMC Palliat Care 2014; 13: 46 CrossRef MEDLINE PubMed Central
26.Porta-Sales J, Garzon-Rodriguez C, Villavicencio-Chavez C, Llorens-Torrome S, Gonzalez-Barboteo J: Efficacy and safety of methadone as a second-line opioid for cancer pain in an outpatient clinic: a prospective open-label study. Oncologist 2016; 21: 981–7 CrossRef MEDLINE PubMed Central
27.Mercadante S, Bruera E: Opioid switching: a systematic and critical review. Cancer Treat Rev 2006; 32: 304–15 CrossRef MEDLINE
28.Baxter LES, Campbell A, DeShields M, et al.: Safe methadone induction and stabilization: report of an expert panel. J Addict Med 2013; 7: 377–86 CrossRef MEDLINE
29.Gagnon B, Bruera E: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999; 18: 120–5 CrossRef
30.Ostgathe C, Voltz R, van Aaaken A, et al.: Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone. Support Care Cancer 2011; 20: 2105–10 CrossRef MEDLINE
31.Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F: Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 3216–21 CrossRef MEDLINE
32.Ayonrinde OT, Bridge DT: The rediscovery of methadone for cancer pain management. Med J Aust 2000; 173: 536–40 MEDLINE
33.Mercadante S: Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med 2012; 13: 399–404 CrossRef MEDLINE
34.Friedman L: Pain management in palliative care. Clinics in Family Practice 2004; 6: 371–93 CrossRef
35.Morley J, Makin M: The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998; 5: 51–8 CrossRef
36.Hagen NA, Wasylenko E: Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999; 18: 369–75 CrossRef
37.Laugsand EA, Jakobsen G, Kaasa S, Klepstad P: Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 2011; 19: 2005–14 CrossRef MEDLINE PubMed Central
38.Holzer P, Ahmedzai SH, Niederle N, et al.: Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009; 5: 145–51 CrossRef MEDLINE
39.Lange B, Kuperwasser B, Okamoto A, et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010; 27: 381–99 CrossRef CrossRef MEDLINE
40.Wild JE, Grond S, Kuperwasser B, et al.: Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010; 10: 416–27 CrossRef MEDLINE
e1.Caraceni A, Hanks G, Kaasa S, et al.: Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68 CrossRef MEDLINE
e2.Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.1, 2015, AWMF-Registernummer: 128/001OL. www.leitlinienprogramm-onkologie.de/index.php?id=80&type=0 (last accessed on 31 July 2017).
e3.National Health Service Scotland—NHS: Scottish palliative care guidelines: choosing and changing opioids 2014. www.palliativecareguidelines.scot.nhs.uk/media/1215/scottish-palliative-care-guidelines-choosing-and-changing-opioids.pdf (last accessed on 31 July 2017).
e4.National Institute for Health and Care Excellence – NICE: Clinical guideline [CG140] palliative care for adults: strong opioids for pain relief 2016. www.nice.org.uk/guidance/cg140 (last accessed on 31 July 2017).
e5.National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology: adult pain (Version 2.2016). www.oralcancerfoundation.org/wp-content/uploads/2016/09/pain.pdf (last accessed on 31 July 2017).
e6.Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) - Ständige Kommission Leitlinien: AWMF-Regelwerk „Leitlinien“, 1st edition 2012. www.awmf.org/leitlinien/awmf-regelwerk.html (last accessed on 31 July 2017).
e7.Roxane Laboratories: Produktinformation—dolophine hydrochloride 2006. www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM142842.pdf (last accessed on 31 July 2017).
e8. Afsharimani B, Kindl K, Good P, Hardy J: Pharmacological options for the management of refractory cancer pain-what is the evidence? Support Care Cancer 2015; 23: 1473–81 CrossRef MEDLINE
e9.Agbalaka A, Schwenke K, Litzenburger B: Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice. MMW Fortschr Med 2012; 154 (Suppl 4): 123–30 MEDLINE
e10.Argoff C, Arnstein P, Stanos S, et al.: Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate. J Opioid Manag 2015; 11: 417–24 CrossRef MEDLINE
e11.Baron R, Eberhart L, Kern KU, et al.: Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract 2017; 17: 678–700 CrossRef MEDLINE
e12.Berland DW, Malinoff HL, Weiner MA, Przybylski R: When opioids fail in chronic pain management: the role for buprenorphine and hospitalization. Am J Ther 2013; 20: 316–21 CrossRef MEDLINE
e13.Bradley AM, Valgus JM, Bernard S: Converting to transdermal fentanyl: avoidance of underdosing. J Palliat Med 2013; 16: 409–11 CrossRef MEDLINE
e14.Broglio K, Pergolizzi J, Kowalski M, Lynch SY, He E, Wen W: Efficacy and safety of once-daily extended-release (ER) hydrocodone in individuals previously receiving ER morphine for chronic pain. Pain Pract 2017; 17: 382–91 CrossRef MEDLINE
e15. Bruera E, Paice JA: Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book 2015: e593–9 MEDLINE
e16.Coluzzi F, Mattia C: OROS(R) hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol 2010; 76: 1072–84 MEDLINE
e17.Gatti A, Reale C, Luzi M, et al.: Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clin Drug Investig 2010; 30 (Suppl 2): 39–47.
e18.Gonzalez-Barboteo J, Trelis-Navarro J, Tuca-Rodriguez A, Gomez-Batiste X: Opioid rotation: a therapeutic choice in the management of refractory cancer pain. Med Clin (Barc) 2010; 135: 617–22.
e19. Gonzalez-Barboteo J, Alentorn XG, Manuel FA, et al.: Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL study. J Opioid Manag 2014; 10: 395–403 CrossRef MEDLINE
e20.Hanaoka K, Yoshimura T, Tomioka T, Sakata H: Clinical study of one-day fentanyl patch in patients with cancer pain—evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy. Masui 2011; 60: 147–56 MEDLINE
e21. Ikeda M, Sonoo H, Kurebayashi J, et al.: A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer. Gan To Kagaku Ryoho 2012; 39: 599–603.
e22.Kanbayashi Y, Hosokawa T, Okamoto K, et al.: Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. Clin J Pain 2011; 27: 664–7 CrossRef MEDLINE
e23.Kern KU, Krings D, Waldmann-Rex S: Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone. MMW Fortschr Med 2014; 156 (Suppl 2): 54–63.
e24.Khojasteh A, Evans W, Reynolds R, Thomas G, Savarese J: Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 2012; 5: 956–61.
e25.Kim HJ, Kim YS, Park SH: Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study. BMC Palliat Care 2015; 14: 41 CrossRef MEDLINE PubMed Central
e26.Lawlor P, Chan R, Tucker T, Creedon B, Bennett K, Pereira J: A pilot phase report of a randomized trial comparing two strategies for switching to methadone in cancer pain (CP) management. Support Care Cancer 2012; 20: 196.
e27.Leppert W: Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep 2010; 62: 578–91 CrossRef
e28.McNamara P: Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliat Med 2012; 16: 425–34.
e29.Mercadante S: Cancer pain. Curr Opin Support Palliat Care 2013; 7: 139–43 CrossRef MEDLINE
e30.Mercadante S, Porzio G, Aielli F, et al.: Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin 2013; 29: 661–6 CrossRef MEDLINE
e31.Mercadante S, Ferrera P, Villari P, Adile C, Casuccio A: Switching from oxycodone to methadone in advanced cancer patients. Support Care Cancer 2012; 20: 191–4 CrossRef MEDLINE
e32.Mücke M, Conrad R, Marinova M, et al.: Dose-finding for treatment with a transdermal fentanyl patch: titration with oral transmucosal fentanyl citrate and morphine sulfate. Schmerz 2016; 30: 560–7 CrossRef MEDLINE
e33.Ravera E, di Santo S, Bosco R, Arboscello C, Chiarlone R: Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain. Aging Clin Exp Res 2011; 23: 328–32 CrossRef
e34.Rhondali W, Tremellat F, Ledoux M, Ciais JF, Bruera E, Filbet M: Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. J Palliat Med 2013; 16: 1382–7 CrossRef MEDLINE
e35.Riley J, Branford R, Droney J, et al.: Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. J Pain Symptom Manage 2015; 49: 161–72 CrossRef MEDLINE
e36.Roberto A, Galli F, Floriani I, Corli O: Are strong opioids equally effective and safe in the treatment of chronic cancer pain? Results from CERP study. Palliative Medicine Conference: 9th world research congress of the european association for palliative care, EAPC 2016 Ireland: Np34-np5.
e37.Roland CL, Setnik B, Cleveland JM, Brown DA: Clinical outcomes during opioid titration following initiation with or conversion to Remoxy(R), an extended-release formulation of oxycodone. Postgrad Med 2011; 123: 148–59 CrossRef MEDLINE
e38.Schwittay A, Schumann C, Litzenburger BC, Schwenke K: Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists. MMW Fortschr Med 2012; 154 (Suppl 3): 85–93.
e39.Schwittay A, Schumann C, Litzenburger BC, Schwenke K: Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists. J Pain Palliat Care Pharmacother 2013; 27: 225–34 CrossRef MEDLINE
e40.Sittl R: Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2017; 20: 25–30.
e41. Trescot AM: Review of the role of opioids in cancer pain. J Natl Compr Canc Netw 2010; 8: 1087–94 CrossRef
e42.Vissers KC, Besse K, Hans G, Devulder J, Morlion B: Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010; 10: 85–93 CrossRef MEDLINE
e43.Wahle K, Krings D, Schwenke K: Pain therapy in the elderly: 7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study. MMW Fortschr Med 2013; 155 (Suppl 1): 25–31.
e44.Wallace M, Rauck R, Moulin D, Thipphawong J, Khanna S, Tudor I: Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res 2012; 36: 343–52.
e45.Webster LR, Brewer R, Morris D, Cleveland JM, Setnik B: Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules. Postgrad Med 2011; 123: 155–64 CrossRef MEDLINE
e46.Webster L, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A: Evaluation of the tolerability of switching patients on chronic full μ-opioid agonist therapy to buccal buprenorphine. Pain Med 2016; 17: 899–907 PubMed Central